Business Description
Crinetics Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US22663K1079
Total Employee Number:
594Compare
Compare
Traded in other countries / regions
CRNX.USA6Z4.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2018-07-18Description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 25.55 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 39.6 | |||||
Beneish M-Score | 23.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.4 | |||||
3-Year EBITDA Growth Rate | -19.3 | |||||
3-Year EPS without NRI Growth Rate | -16.1 | |||||
3-Year FCF Growth Rate | -22 | |||||
3-Year Book Growth Rate | 20.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.76 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 270.13 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.44 | |||||
9-Day RSI | 88.54 | |||||
14-Day RSI | 89.71 | |||||
3-1 Month Momentum % | 140.01 | |||||
6-1 Month Momentum % | 90.59 | |||||
12-1 Month Momentum % | 184.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.57 | |||||
Quick Ratio | 15.53 | |||||
Cash Ratio | 15.09 | |||||
Days Inventory | 2946.81 | |||||
Days Sales Outstanding | 52.62 | |||||
Days Payable | 13645.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.1 | |||||
Shareholder Yield % | -4.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.16 | |||||
Operating Margin % | -1302.52 | |||||
Net Margin % | -1189.88 | |||||
EBITDA Margin % | -1292.46 | |||||
FCF Margin % | -1008.58 | |||||
OCF Margin % | -1002.27 | |||||
ROE % | -43.94 | |||||
ROA % | -39.59 | |||||
ROIC % | -484.57 | |||||
3-Year ROIIC % | -342.54 | |||||
ROC (Joel Greenblatt) % | -1008.05 | |||||
ROCE % | -46.09 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 207.6 | |||||
PB Ratio | 7.51 | |||||
Price-to-Tangible-Book | 7.51 | |||||
EV-to-EBIT | -14.25 | |||||
EV-to-Forward-EBIT | 5.94 | |||||
EV-to-EBITDA | -14.36 | |||||
EV-to-Revenue | 185.66 | |||||
EV-to-Forward-Revenue | 67.63 | |||||
EV-to-FCF | -18.41 | |||||
Price-to-GF-Value | 0.09 | |||||
| Price-to-Net-Current-Asset-Value | 8.04 | |||||
| Price-to-Net-Cash | 8.33 | |||||
Earnings Yield (Greenblatt) % | -7.02 | |||||
FCF Yield % | -4.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Crinetics Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 42.156 | ||
| EPS (TTM) ($) | -5.04 | ||
| Beta | -0.669 | ||
| 3-Year Sharpe Ratio | 0.81 | ||
| 3-Year Sortino Ratio | 3.12 | ||
| Volatility % | 127.99 | ||
| 14-Day RSI | 89.71 | ||
| 14-Day ATR ($) | 0.67874 | ||
| 20-Day SMA ($) | 84.102 | ||
| 12-1 Month Momentum % | 184.95 | ||
| 52-Week Range ($) | 28.73 - 84.795 | ||
| Shares Outstanding (Mil) | 106.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Crinetics Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crinetics Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 79 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 78 days | ||
| Second quarter earnings results for 2026 | 2026-08-03 | 83.52 (-0.27%) | ||
| General meeting for 2026 | 2026-06-18 08:00 | 35.75 (+2.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 41.71 (+1.56%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 41.71 (+1.56%) | ||
| TD Cowen 46th Annual Health Care Conference, | 2026-03-04 13:50 | 40.12 (+1.13%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 16:30 | 43.39 (-2.14%) | ||
| Annual report for 2025 | 2026-02-26 | 43.39 (-2.14%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 43.39 (-2.14%) |
Show
Entries
Crinetics Pharmaceuticals Inc Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc(CRNX)'s stock price today?
The current price of CRNX is $84.69. The 52 week high of CRNX is $84.80 and 52 week low is $28.73.
When is next earnings date of Crinetics Pharmaceuticals Inc(CRNX)?
The next earnings date of Crinetics Pharmaceuticals Inc(CRNX) is 2026-11-06 Est..
Does Crinetics Pharmaceuticals Inc(CRNX) pay dividends? If so, how much?
Crinetics Pharmaceuticals Inc(CRNX) does not pay dividend.
Guru Commentaries on NAS:CRNX
No articles.
Press Release
Articles on Crinetics Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers